BACKGROUND: In Germany, the 12-month prevalence of methamphetamine use among persons aged 15 to 34 is 1.9%. An increasing number of newborns are being born after a prenatal methamphetamine exposure (PME). In 2014, in the German state of Saxony, approximately four out of 1000 newborns were affected. METHODS: This systematic review (Prospero registration number CRD42017060536) includes publications that were published between January 1990 and November 2019. The purpose was to determine the effects of PME on the peri- and neonatal condition of the affected children and on their further long-term development. Observational studies with a control group were included in the review and examined for their methodological quality. RESULTS: 31 publications, which dealt with two prospective and six retrospective cohort studies, were included in the review. The studies involved a total of 4446 mother-child pairs with PME, compared with 43 778 pairs without PME. A metaanalysis revealed that PME was associated with, among other findings, lower birth weight (SMD = -0.348; 95% confidence interval [-0.777; 0.081]), shorter body length (SMD= -0.198 [-0.348; -0.047]), and smaller head circumference (SMD= -0.479 [-1.047; 0.089]). Some differences between the groups with and without PME persist into the toddler years. Moreover, children with PME much more commonly display psychological and neurocognitive abnormalities, which are more severe in children growing up in problematic surroundings (discord, violence, poverty, low educational level of the parent or caregiver). A limitation of this review is that not all studies employed an objective or quantitative measure of methamphet - amine use. CONCLUSION: The documented effects of PME on child development necessitate early treatment of the affected expectant mothers, children, and families. Emphasis should be placed on structured and interdisciplinary preventive measures for methamphetamine use.
BACKGROUND: In Germany, the 12-month prevalence of methamphetamine use among persons aged 15 to 34 is 1.9%. An increasing number of newborns are being born after a prenatal methamphetamine exposure (PME). In 2014, in the German state of Saxony, approximately four out of 1000 newborns were affected. METHODS: This systematic review (Prospero registration number CRD42017060536) includes publications that were published between January 1990 and November 2019. The purpose was to determine the effects of PME on the peri- and neonatal condition of the affected children and on their further long-term development. Observational studies with a control group were included in the review and examined for their methodological quality. RESULTS: 31 publications, which dealt with two prospective and six retrospective cohort studies, were included in the review. The studies involved a total of 4446 mother-child pairs with PME, compared with 43 778 pairs without PME. A metaanalysis revealed that PME was associated with, among other findings, lower birth weight (SMD = -0.348; 95% confidence interval [-0.777; 0.081]), shorter body length (SMD= -0.198 [-0.348; -0.047]), and smaller head circumference (SMD= -0.479 [-1.047; 0.089]). Some differences between the groups with and without PME persist into the toddler years. Moreover, children with PME much more commonly display psychological and neurocognitive abnormalities, which are more severe in children growing up in problematic surroundings (discord, violence, poverty, low educational level of the parent or caregiver). A limitation of this review is that not all studies employed an objective or quantitative measure of methamphet - amine use. CONCLUSION: The documented effects of PME on child development necessitate early treatment of the affected expectant mothers, children, and families. Emphasis should be placed on structured and interdisciplinary preventive measures for methamphetamine use.
Authors: Nwando Eze; Lynne M Smith; Linda L LaGasse; Chris Derauf; Elana Newman; Amelia Arria; Marilyn A Huestis; Sheri A Della Grotta; Lynne M Dansereau; Charles Neal; Barry M Lester Journal: J Pediatr Date: 2016-01-11 Impact factor: 4.406
Authors: Lynne M Smith; Linda L LaGasse; Chris Derauf; Penny Grant; Rizwan Shah; Amelia Arria; Marilyn Huestis; William Haning; Arthur Strauss; Sheri Della Grotta; Jing Liu; Barry M Lester Journal: Pediatrics Date: 2006-09 Impact factor: 7.124
Authors: Monica S Paz; Lynne M Smith; Linda L LaGasse; Chris Derauf; Penny Grant; Rizwan Shah; Amelia Arria; Marilyn Huestis; William Haning; Arthur Strauss; Sheri Della Grotta; Jing Liu; Barry M Lester Journal: Neurotoxicol Teratol Date: 2008-12-03 Impact factor: 3.763
Authors: Chulathida Chomchai; Natawadee Na Manorom; Pornchai Watanarungsan; Panitan Yossuck; Summon Chomchai Journal: Southeast Asian J Trop Med Public Health Date: 2004-03 Impact factor: 0.267
Authors: Jean Twomey; Linda LaGasse; Chris Derauf; Elana Newman; Rizwan Shah; Lynne Smith; Amelia Arria; Marilyn Huestis; Sheri DellaGrotta; Mary Roberts; Lynne Dansereau; Charles Neal; Barry Lester Journal: Am J Orthopsychiatry Date: 2013-01
Authors: Beau Abar; Linda L LaGasse; Trecia Wouldes; Chris Derauf; Elana Newman; Rizwan Shah; Lynne M Smith; Amelia M Arria; Marilyn A Huestis; Sheri DellaGrotta; Lynne M Dansereau; Tara Wilcox; Charles R Neal; Barry M Lester Journal: Prev Sci Date: 2014-10
Authors: Linda Chang; Kenichi Oishi; Jon Skranes; Steven Buchthal; Eric Cunningham; Robyn Yamakawa; Sara Hayama; Caroline S Jiang; Daniel Alicata; Antonette Hernandez; Christine Cloak; Tricia Wright; Thomas Ernst Journal: JAMA Psychiatry Date: 2016-12-01 Impact factor: 21.596
Authors: Johannes Petzold; Laura Rehmet; Benjamin Weber; Maik Spreer; Maria Krüger; Ulrich S Zimmermann; Maximilian Pilhatsch Journal: Front Psychiatry Date: 2022-05-27 Impact factor: 5.435